Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans

Published:2012-10-18 Issue:5 Volume:43 Page:432-442
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Furuta Shinji,Smart Clair,Hackett Andrew,Benning Rajdeep,Warrington Steve

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/00498254.2012.731618

Reference36 articles.

1. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events

2. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile)

3. Identification and Characterization of Human Organic Anion Transporter 3 Expressing Predominantly in the Kidney

4. Transport of Cyclic Nucleotides and Estradiol 17-β-d-Glucuronide by Multidrug Resistance Protein 4

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease;Endocrinology and Metabolism;2024-08-31

2. Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis;Medicine;2024-07-12

3. The Structure-property Relationships of Clinically Approved Protease Inhibitors;Current Medicinal Chemistry;2024-04

4. In vivo and in vitro metabolite profiling of nirmatrelvir using LC–Q‐ToF–MS/MS along with the in silico approaches for prediction of metabolites and their toxicity;Biomedical Chromatography;2024-02-25

5. Development and Validation of a Stability-Indicating Related Substances RP-HPLC Method for Anagliptin and its Degradation Products;Pharmaceutical Chemistry Journal;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3